Agilent Technologies, a major player in analytical and clinical laboratory services, has agreed to acquire Canadian biotech and pharmaceutical CDMO Biovectra from HIG Capital in a $925 million deal that is expected to close before 2025. This covers all Biovectra’s employees and sites in Prince Edward Island and Nova Scotia.

“The acquisition expand Agilent’s end-to-end biopharma solutions with Biovectra’s biologics capabilities to accelerate drug development and manufacturing,” the two companies stated. Industry rumour had previously linked Biovectra with Thermo Fisher.